NSE · ZOTA
Zota Health Care Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹126 Cr with net profit ₹1 Cr — a 0.89% net margin, versus 1.5% the period before.
Shareholding
As of 2026-09-30
- Promoter49.38%
- Public36.4%
- FII6.92%
- DII7.3%
14,928 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.7× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #38 of 102 by market cap · medians across 49 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,46,276 Cr | 36.26 | 5 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,26,433 Cr | 94.35 | 20.82 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,19,491 Cr | 26.29 | 4.29 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,14,683 Cr | 40.96 | 2.95 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,13,991 Cr | 36.71 | 3.22 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,04,913 Cr | 44.96 | 5.97 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,03,568 Cr | 25.52 | 2.62 | 10.13% | 10.88% |
| Lupin Limited | ₹90,914 Cr | 16.14 | 3.78 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹73,096 Cr | 23.42 | 6.53 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹63,334 Cr | 27.79 | 4.56 | 16.66% | 14.31% |
| Zota Health Care Limited(this company) | ₹4,264 Cr | — | 6.82 | -18.03% | -16.61% |
AI analysis
AI-generated · google/gemini-2.5-flashZota Health Care Limited, listed under the symbol ZOTA, has a market capitalization of Rs 4610 Cr. The company reported revenue of Rs 295.04 Cr with a revenue growth of 62.3%. It has a negative profit margin of -13.73% and a debt-to-equity ratio of 0.75. The stock's 52-week high is Rs 1740 and the 52-week low is Rs 1026.2.
Positives
- +Revenue increased by 62.3% to Rs 295.04 Cr.
- +The dividend yield is 8%, indicating a significant payout to shareholders.
- +The number of shareholders has increased to 14,005 as of March 2026.
Negatives
- −The company reported a negative profit margin of -13.73%.
- −Return on Equity (ROE) is negative at -10.66%.
- −Return on Capital Employed (ROCE) is negative at -6.48%.
- −The company has an EPS of 0.
- −Promoter shareholding includes 0.26% pledged shares.
Financial performance
Zota Health Care Limited's revenue for the latest reported period is Rs 295.04 Cr, marking a growth of 62.3%. However, the company experienced a negative profit margin of -13.73%. In the quarter ending March 2026, the company reported revenue of Rs 163.18 Cr and a net profit of -Rs 14.17 Cr. This follows a net profit of -Rs 29.5 Cr on revenue of Rs 142.95 Cr in December 2025.
Profitability & returns
The company's profitability and returns indicators show challenges. The Return on Equity (ROE) is -10.66% and the Return on Capital Employed (ROCE) is -6.48%. The earnings per share (EPS) is 0 for the latest period. Quarterly net profit has been negative for the past six quarters, with the latest being -Rs 14.17 Cr in March 2026.
Balance sheet
Zota Health Care Limited has a book value of Rs 200.24. The debt-to-equity ratio stands at 0.75. The company's market capitalization is Rs 4610 Cr. There is no information available regarding current assets, liabilities, or cash flow.
Ownership & pledges
As of March 31, 2026, the promoter holding in Zota Health Care Limited is 49.3844%, with public shareholding at 35.6915%. A portion of the promoter shares are pledged, with a promoter pledge percentage of 0.26%.
Regulatory & surveillance
One promoter, Dhara Mehta, has 44,000 pledged shares as of March 31, 2026, representing 31.85% of her total shareholding. There is no information on any regulatory or surveillance actions against the company.
Data as of — price: 2026-11-07 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.